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Extensive transcriptional and ontogenetic diversity
exists among normal tissue-resident macrophages,
with unique transcriptional profiles endowing the
cells with tissue-specific functions. However, it is
unknown whether the origins of different macro-
phage populations affect their roles in malignancy.
Given potential artifacts associated with irradiation-
based lineage tracing, it remains unclear if bone-
marrow-derived macrophages (BMDMs) are present
in tumors of the brain, a tissue with no homeostatic
involvement of BMDMs. Here, we employed multiple
models of murine brain malignancy and genetic line-
age tracing to demonstrate that BMDMs are abun-
dant in primary and metastatic brain tumors. Our
data indicate that distinct transcriptional networks
in brain-resident microglia and recruited BMDMs
are associated with tumor-mediated education
yet are also influenced by chromatin landscapes
established before tumor initiation. Furthermore, we
demonstrate that microglia specifically repress
Itga4 (CD49D), enabling its utility as a discriminatory
marker between microglia and BMDMs in primary
and metastatic disease in mouse and human.INTRODUCTION
Macrophages are terminally differentiated cells of the myeloid
lineage, with critical functions in tissue development and homeo-
stasis (Okabe and Medzhitov, 2016). These cells serve as aCell Repo
This is an open access article undnexus between adaptive and innate immunity, regulating re-
sponses to inflammation and wound healing (Mosser and
Edwards, 2008). To facilitate these diverse functions, macro-
phages employ considerable plasticity in response to a range
of cytokines. These responses fall within a spectrum of different
phenotypes ranging from classically activated pro-inflammatory
macrophages to alternatively activated anti-inflammatory mac-
rophages (Xue et al., 2014).Macrophages also possess substan-
tial diversity and plasticity, with recent studies revealing impor-
tant insights into the developmental origins of tissue-resident
macrophages and uncovering tissue-specific gene expression
patterns and enhancer landscapes (Gautier et al., 2012; Ginhoux
et al., 2010; Gomez Perdiguero et al., 2015; Lavin et al., 2014;
Mass et al., 2016).
While the local tissue environment sculpts macrophage tran-
scriptional profiles and epigenetic states in homeostasis (Lavin
et al., 2014), it is unknown whether an inflammatory tissue envi-
ronment may promote differences between macrophage popu-
lations of distinct ontogenies. This is particularly relevant in can-
cer, where tumor-associated macrophages (TAMs) are derived
from monocytes and also potentially from tissue-resident mac-
rophages (Du et al., 2008; Pyonteck et al., 2013; Solga et al.,
2015).
Brain-resident macrophages, microglia (MG), develop from er-
ythromyeloid precursors in the yolk sac (Gomez Perdiguero
et al., 2015; Kierdorf et al., 2013a; Schulz et al., 2012). Unlike
other tissue-resident macrophages, during homeostasis, MG
undergo self-renewal and their pool is not replenished by mono-
cytes (Ajami et al., 2007). Microglia are also resistant to myeloa-
blative irradiation (Kennedy and Abkowitz, 1997). Indeed, this
property has been used extensively in bone marrow transplanta-
tion (BMT) models to distinguish radio-resistant MG from BM-
derived macrophages (BMDMs) (Huang et al., 2014; Sedgwick
et al., 1991). However, only under conditions of blood-brainrts 17, 2445–2459, November 22, 2016 ª 2016 The Authors. 2445
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Figure 1. Lineage Tracing Systems Demonstrate Heterogeneity in TAM Ontogeny in Multiple Models of Glioma
(A) Experimental scheme for the GEMM-shP53 model (see Supplemental Experimental Procedures for details). Representative flow cytometry panels for
TdTomato and GFP are shown for Cd45+Cd11b+Ly6GLy6C microglia (MG), Cd45+Cd11b+Ly6GLy6C+ monocytes, and Cd45+Cd11b+Ly6GLy6C TAMs
from GEMM-shP53 gliomas.
(B) Quantitation of TdTomato+ and GFP+ monocytes (Mono) and granulocytes (Gran) in peripheral blood, MG in non-tumor-bearing brain, and monocytes,
granulocytes, and TAMs in GEMM-shP53 gliomas as depicted in (A). Bars represent mean and SEM (n = 3–5 for each group).
(C) Representative immunofluorescence (IF) staining of Iba1 (white), GFP (green), and DAPI (blue) in a GEMM-shP53 tumor as depicted in (A). Scale bar, 50 mm.
Data are representative of n = 5 tumors.
(D) Experimental design for Cx3cr1 lineage-tracing model (see Experimental Procedures for details). Monocytes, MG, and TAMswere isolated as described in (A)
and evaluated for TdTomato and YFP reporter expression. Data are representative of n = 3 mice.
(legend continued on next page)
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barrier (BBB) disruption (e.g., via irradiation [IR] or chemical
manipulation) does there appear to be a significant contribution
of BMDMs to the brain macrophage pool in a non-pathological
context (Bruttger et al., 2015; Mildner et al., 2007). This is rele-
vant to brain tumors such as gliomas, where there is also disrup-
tion of the BBB with disease progression (Dubois et al., 2014).
IR-BMT has shown BMDM abundance in murine CNS cancers
(Biffi et al., 2004; De Palma et al., 2005; Huang et al., 2014; M€uller
et al., 2015; Pyonteck et al., 2013); however, given the current
lack of markers definitively distinguishing MG and BMDMs, it
remains unclear if BMDM recruitment indeed occurs in brain
tumors in the absence of irradiation. The need for markers distin-
guishing these cells is especially critical in human disease, where
lineage tracing is not possible.
Here, we utilize multiple genetic lineage tracing models to
demonstrate that BMDMs are indeed present in murine brain
tumors. Gene expression profiling showed that while BMDMs
and MG share features of tumor education, they also exhibit
distinct activation modes. Our data suggest these faculties
are a result of inherent transcriptional networks poised before
the onset of tumorigenesis, where ontogeny pre-biases cells
to engage in distinct macrophage activation states. Lastly, we
identify markers that distinguish MG and peripherally derived
macrophages under homeostasis, as well as in glioma and brain
metastasis in both mice and humans.
RESULTS
Tumor-Associated BMDMs Are Present in Mouse
Glioma Models
To track the ontogeny of myeloid cells in murine gliomas, we
utilized a hematopoietic lineage tracing system, Flt3:Cre;
Rosa26:mTmG, which has been used to show that peripheral
myeloid cells develop from Flt3+ short-term hematopoietic
stem cells (ST-HSCs) and are GFP+, while parenchymal MG
develop independently of ST-HSC precursors and are thus
negative for the GFP reporter, remaining TdTomato+ (Boyer
et al., 2011; Gomez Perdiguero et al., 2015). In non-tumor-
bearing mice, >98% of blood monocytes were GFP+, and
<1% of MG showed recombination for the mTmG reporter (Fig-
ure 1A). The spleen was composed of GFP+ lymphocyte-rich
follicles, surrounded by TdTomato+ stromal cells, while the
brain parenchyma did not contain any detectable GFP+ cells
(Figure S1A).
We next bred this line to the nestin:Tva (nTva) line to trace
myeloid cell ontogeny in a genetically engineered mouse
model (GEMM) of glioma. We induced gliomas by intracranial in-(E) Flow cytometry quantitation of TdTomato+ and TdTomatomonocytes and gra
granulocytes, and TAMs in GL261 gliomas as depicted in (D). Bars represent me
(F) Representative IF staining for Iba1 (green), TdTomato (red), and DAPI (blue) in
(G) Pairwise correlation matrix of normalized RNA-seq counts frommonocytes (n =
GEMM-shP53 TAM MG, GEMM-shP53 TAM BMDMs, GL261 TAM MG, and GL2
(H) Diagram depicting different modules of TAM education compared to normal
(I) Differentially expressed genes between normal MG and the four TAM populat
genes shared between the different groups.
(J) Representative IF staining of Ki67+ TAM BMDMs and TAM MG in the GEMM-
green; omitted from top panel). Scale bars represent 100 mm (top panel) and 10jection of DF1 cells transfected with RCAS vectors encoding
platelet-derived growth factor b (PDGFB) and a short hairpin
against P53 (Ozawa et al., 2014) (Figure 1A), termed GEMM-
shP53 herein. Flow cytometry of end-stage gliomas demon-
strated that all monocytes (Cd45+Cd11b+Ly6ChighLy6G) and
granulocytes (Cd45+Cd11b+Ly6ClowLy6Ghigh) in the tumor
were GFP+ (Figure 1B), while the bulk TAM compartment
(Cd45+Cd11b+Ly6CLy6G) was composed of both GFP+
TAM BMDMs and GFP TAM MG (Figures 1A, 1B, and S1B),
confirmed by tissue immunofluorescence (IF) co-staining with
the pan-macrophage marker Iba1 (Figure 1C). By contrast, the
contralateral, non-malignant brain contained only GFP MG,
demonstrating the specific abundance of TAM BMDMs only
within the tumor mass (Figure 1B).
We and others have utilized IR-BMT to show that TAM
BMDMs are recruited to murine gliomas (Huang et al., 2014;
Pyonteck et al., 2013). However, IR can lead to ectopic recruit-
ment of BMDMs to the brain and thereby increase their relative
abundance (M€uller et al., 2015). We verified these findings in
the orthotopic, syngeneic GL261 glioma model and found the
TAM compartment was composed of both TAM MG and TAM
BMDMs using both IR-BMT lineage tracing and IR-independent
Flt3:Cre lineage tracing (Figures S1C and S1D). TAM BMDM
abundance was significantly increased in the IR-BMT model
compared to the Flt3:Cre model (Figure S1D), reinforcing previ-
ous reports that IR-BMT can skew the ratio of MG and BMDMs.
Critically, however, using Flt3:Cre lineage tracing, we found that
BMDMs composed >35% of the bulk TAM population in gliomas
without IR preconditioning, demonstrating that BMDM infiltration
into tumors is not solely an artifact of IR (Figure S1D).
To exclude the possibility that this finding was due to a
subset of TAM MG spontaneously upregulating Flt3 expression,
we utilized a complementary lineage-tracing approach previ-
ously indicated to be specific for MG in the normal brain:
Cx3cr1:CreER-IRES YFP; Rosa26:lsl-TdTomato (see Supple-
mental Experimental Procedures for details) (Parkhurst et al.,
2013). 3 days after tamoxifen-induced labeling, >99% of MG
and circulating monocytes were TdTomato+ (Figure S1E). How-
ever, after 3 weeks, blood monocytes no longer retained the
TdTomato+ reporter, indicating their turnover and replenishment
by tamoxifen-‘‘naive’’ monocytes (Figure S1E). By contrast,
>99% of MG remained TdTomato+ (Figure S1E). We induced
GL261 tumors in these mice, at 7 weeks of age, and observed
both TdTomato+ TAM MG and TdTomato TAM BMDMs
(Figures 1D and 1E). Meanwhile, all monocytes and granulocytes
were TdTomato in the tumor and periphery (Figure 1E).
These findings were substantiated by IF co-staining of tissuenulocytes in peripheral blood, MG in non-tumor-bearing brain, andmonocytes,
an and SEM (n = 3 for each group).
a GL261 tumor. Scale bar, 50 mm.
5), normal MG (n = 3), and the four TAM populations from the different models:
61 TAM BMDMs (n = 3 for each group).
MG.
ions were tabulated. Bar chart depicts the number of differentially expressed
shP53 model as depicted in (A) (Ki67, white; CD68, red; DAPI, blue; and GFP,
mm (lower panels). Data are representative of n = 5 tumors.
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sections with Iba1 (Figure 1F). Importantly, there was a gradient
of eYFP reporter expression levels, with highest expression in
TdTomato+ TAM MG, slightly lower levels in TdTomato TAM
BMDMs, and lowest levels in monocytes (Figure S1F), demon-
strating the capacity of TAM BMDMs to express Cx3cr1 in brain
tumors. Thus,Cx3cr1 expression alone cannot be used to strictly
identify MG in gliomas. Together, these complementary genetic
lineage-tracing models show that BMDMs contribute to the TAM
pool in several murine models of glioma, in the absence of IR.
RNA Sequencing Reveals Multimodal Patterns of TAM
Education
We next analyzed the transcriptional profiles of TAM MG
and TAM BMDMs in gliomas. We performed RNA-sequencing
(RNA-seq) on sorted populations of TAM MG and TAM BMDM
from GEMM-shP53 and GL261 tumors using the Flt3-based
and Cx3cr1-based lineage tracing systems, respectively. We
also collected MG and Ly6Chigh blood monocytes from non-
tumor-bearing Flt3:Cre Rosa26:mTmG mice. Global correlation
analyses revealed distinct clustering of all TAM populations
from normal MG and monocytes, with further cell-type-specific
and tumor-specific clustering (Figure 1G). As expected, mono-
cytes were enriched for Ly6c2 expression, while both TAM MG
and TAM BMDMs expressed higher levels of macrophage
differentiation markers (e.g., Aif1 and Mertk) than monocytes
(Figure S1G). Normal MG and TAM MG expressed higher levels
of MG-enriched genes (e.g., Cx3cr1, P2ry12, and Tmem119)
than monocytes and TAM BMDMs (Figure S1G).
We next delineated cell-type-specific, tumor-specific, and
conserved patterns of tumor education among TAMs (Figure 1H).
We identified differentially expressed genes between each TAM
population from GEMM-shP53 and GL261 tumors compared to
normal MG and monocytes (Figures 1I and S1H; Table S1A).
Using normal MG as the reference, we found 91 genes specif-
ically upregulated in TAM MG from both GEMM-shP53 and
GL261 models (Figure 1I, red bar), and 342 genes upregulated
in TAM BMDMs from both GEMM-shP53 and GL261 models
(Figure 1I, green bar). We also identified genes that were specif-
ically upregulated in TAM MG and TAM BMDMs from either the
GEMM-shP53 (n = 102) or GL261 (n = 778) models. The largest
gene set (n = 1383) was significantly upregulated in all TAM pop-
ulations compared to normal MG (Figure 1I, orange bar). Similar
patterns of expression were observed when monocytes were
used as the reference population (Figure S1H; Table S1B).
Many cell-cycle-related genes were upregulated, suggesting
increased TAM proliferation compared to normal MG andmono-
cytes (Tables S1A and S1B). Indeed, we found Ki67+ cells in both
Iba1+GFP+ TAM BMDM and Iba1+GFP TAM MG in the Flt3-
based lineage-tracingmodel (Figure 1J).Conservedupregulation
of complement-related factors, extracellularmatrix components,
proteases, lipid metabolismmediators, and clotting factors were
also evident in both TAM populations (Table S1A). In addition
to these programmatic changes, compared to normal MG, there
wasupregulation of growth factors (Igf1,Areg, andOsm), chemo-
kines and cytokines (Spp1, Ccl5, Cxcl9, and Cxcl10), and other
immune modulators, including Cd274/PD-L1 and major histo-
compatibility complex (MHC class) I molecules (H2-K1, H2-D1,
and B2m) (Table S1A). A similar distribution of differentially ex-2448 Cell Reports 17, 2445–2459, November 22, 2016pressed genes was evident in comparing the TAM populations
from both gliomamodels to bloodmonocytes (Figure S1H; Table
S1B). Interestingly, we found several MG-enriched genes (e.g.,
Tmem119, Olfml3, Lag3, Jam2, and Sparc) (Gautier et al., 2012)
enriched in TAM BMDMs in both GL261 and GEMM-shP53
models compared to monocytes (Table S1B). Despite this differ-
ence, there was still higher expression of MG-related genes in
normal MG and TAMMG than in TAMBMDMs.Meanwhile, other
MG-enriched genes showed no such induction in TAM BMDMs
(P2ry12, Sall1, andMef2c). Collectively, thesedata are consistent
with Cx3cr1 upregulation specifically in gliomas (Figure S1F)
and the notion that macrophages acquire tissue-resident gene
expression upon infiltration into a foreign tissue (Gosselin et al.,
2014; Lavin et al., 2014).
TAM BMDMs and TAM MG Possess Distinct Education
Patterns
We investigated transcriptional differences between TAMs
derived from BMDMs versus MG and identified 378 differentially
expressed genes enriched in TAM MG compared to TAM
BMDMs in both GEMM-shP53 and GL261 models and 485
genes enriched in TAM BMDMs compared to TAM MG (Fig-
ure 2A; Table S2). As expected, among the 378 TAM MG genes,
we found markers previously shown to be enriched in MG
compared to other macrophage populations, including P2ry12,
Tmem119, Slc2a5, Pros1, and Sall1 (Figure 2A) (Gautier et al.,
2012). Consistent with their tissue-specific functions, we found
that normal MG and TAM MG were enriched for Jam2 and
Ocln (Figure S2A; Table S2), integral components of the blood-
brain barrier (Liu et al., 2012). Similarly, TAM MG expressed
higher levels of classical complement factors C4b, C2, and Cfh
(Figure S2A), a pathway important for MG function in synaptic
pruning and host defense (Stephan et al., 2012).
Meanwhile, TAM BMDMs expressed high levels of alternative
complement cascade components Cfb and Cfp (Figure S2A)
and enrichment of many immune effectors, including Cd40,
Jak2, Ifitm1, Ifitm2, Tlr11, Tlr5, Tlr8, Mefv, and Fas (Figure S2A).
In the GEMM-shP53 model, interleukin 1 (IL-1) pathway ligands
were differentially expressed, with Il1a enriched in TAM MG
and Il1b in TAM BMDMs, and similar trends were observed in
the GL261 model (Figure S2B). While Il1r1 levels did not signifi-
cantly differ, TAM BMDMs expressed higher levels of the IL-1
signaling antagonist Il1rn, and the IL-1 decoy receptor Il1r2
(Figure S2B). These results complement reports in non-cancer
contexts demonstrating Il1a enrichment in MG compared to
BMDMs, where IL-1 signaling played a critical role in MG repo-
pulation and maintenance (Bruttger et al., 2015).
We next interrogated chemokines, growth factors, and immune
modulators associated with different macrophage activation
states. In addition to model-specific gene expression changes
(Figure S2C; Table S3), we found in both GEMM and GL261
models that TAMBMDMswere enriched for chemokines involved
in wound healing, including Ccl22, Ccl17, Cxcl2, Cxcl3, and
Cxcl16 (Figure 2B) (Xue et al., 2014). Interestingly, TAM MG were
enriched for expression of Ccl4 and Tnf, chemokines associated
with a pro-inflammatory response (Xue et al., 2014). This differ-
ence in activation states was supported by a programmatic in-
crease in antigen presentation centered on increased expression
Figure 2. TAM BMDMs and TAM MG Possess Distinct Gene Expression Patterns
(A) Scatterplot depicting log10 (p value)3 sign (fold change) between TAM BMDMs and TAMMG in GEMM-shP53 gliomas (x axis) and GL261 gliomas (y axis).
Significantly upregulated genes (log2 fold change of more than ±1 and FDR < 1%) are in green for BMDM and red for MG.
(B) Heatmap depicting row-normalized log2 gene expression values for indicated genes in GL261 TAM BMDMs (dark green), GEMM-shP53 TAM BMDMs (light
green), GL261 TAM MG (dark red), and GEMM-shP53 TAM MG (light red).
(C) Bar plots depicting normalized gene expression values for indicated genes in these four different TAM populations. Bars represent mean ± SEM.
(D) Representative IF staining in GEMM-shP53 Flt3:Cre Rosa26:mTmG gliomas and adjacent normal brain for Cd68 (red, Alexa Fluor 594), GFP (green), andMHC
II (white). DAPI is shown in blue, and TdTomato fluorescence is not shown. Scale bar, 100 mm. Data are representative of n = 5 tumors.
(E) Venn diagram depicting significantly upregulated genes in BMDMs versus MG in GL261model, GEMM-shP53, and non-malignant brain (GSE68376 dataset).
Select genes are listed.
(F) Boxplot of core BMDM genes (Figure 2E) and core MG genes (Figure S2D), where each data point represents the Z scored expression of a gene across the
indicated cell populations using available datasets from the Immunological Genome Project.
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of theMHC IImaster regulatorCiita (Reith et al., 2005) and its tran-
scriptional targets H2-Aa, H2-DMb1, H2-Eb1, and Cd74 in TAM
BMDMs (Figure 2C). IF staining in Flt3:Cre; GEMM-shP53 tumors
revealed a marked increase in MHC II in tumors, compared
to adjacent brain, restricted to GFP+ TAM BMDMs (Figure 2D).
In addition to this antigen-presentation program, costimulatory
molecules such as Cd80, Cd40, and Cd200r4 were increased
(Figure S2A). These findings were further complemented by
TAMBMDM-enriched expression of the Aryl-hydrocarbon recep-
tor (Ahr), a transcription factor previously shown to mediate
immune suppression (Murray et al., 2014; Opitz et al., 2011) (Fig-
ure S2A). Critically, we also found that the immunosuppressive
cytokine Il10 was enriched in TAM BMDMs compared to TAM
MG (Figure 2B). Collectively, these results suggest that TAM
BMDMsengage in a chronicwound-healing-like state reminiscent
of an alternatively activated macrophage (Mosser and Edwards,
2008). Similar phenotypes have been shown in models of oligo-
dendrocyte cell death, where, despite high MHC II expression,
myeloid cells did not activate a robust T cell response (Locatelli
et al., 2012), suggestive of a tolerogenic program.
We next asked if the differences in inflammatory mediators
were an inherent feature of BMDMs upon entry into the brain
or rather a consequence of tumor education. Previous studies
demonstrated that when MG are depleted and the brain precon-
ditioned by IR, BMDMs can seed the brain and contribute signif-
icantly to the brain macrophage pool (hereafter termed ‘‘ectopic
BMDM’’ in a normal ‘‘repopulated brain’’) (Bruttger et al., 2015).
We used this dataset for comparative analyses with our TAM
BMDMs and TAM MG RNA-seq data to discriminate tumor
education differences from ontogenetic, non-tumor-associated
differences. This juxtaposition allowed us to identify genes en-
riched in TAM MG versus TAM BMDMs as well as normal MG
versus ‘‘ectopic’’ BMDMs. These ‘‘core’’ MG genes included
not only known MG markers such as Jam2, Siglech, and
P2ry12 but also complement factors C2, C4b, and Cfh as well
as the pro-inflammatory cytokines Ccl4 and Tnf (Figure S2D,
n = 245 genes; Table S4). We identified genes enriched in TAM
BMDMs (n = 294) specifically in the context of a tumor, including
Il10, Cxcl2, Cxcl3, Ccl17, Ccl22, and H2-Dmb1 (Figure 2E). In
contrast to this tumor-specific expression profile, there were
also 164 core BMDM genes enriched in BMDM compared to
MG, regardless of the presence or absence of a tumor, including
Ciita, Ahr, Runx2, Runx3, Vav3, and Vdr (Figure 2E; Table S4).
These data indicate some features distinguishing TAM BMDMs
and TAM MG are inherent to their differential ontogenies, while
others are only acquired upon interaction with, and education
by, the tumor microenvironment.
As many of the core BMDM genes are central players in innate
immunity, we queried the immunological genome project data-
base to determine if these genes were over-represented in any
particular myeloid cell population. Interestingly, we found that
these genes were actually repressed in MG compared to tis-
sue-resident macrophages of the BM, spleen, lung, peritoneum,
small intestine, and monocyte progenitors (Figure 2F). Mean-
while, core MG genes were indeed enriched in MG compared
to other myeloid cells (Figure 2F). These data suggest that core
BMDM genes are not specifically enriched in TAM BMDMs or
macrophages in general but are specifically repressed in MG.2450 Cell Reports 17, 2445–2459, November 22, 2016Recent studies have highlighted extensive epigenetic diversity
among tissue-resident macrophages (Lavin et al., 2014); thus, we
hypothesized that the MG-repressed genes may be epigeneti-
cally altered in MG compared to even the distantly related mono-
cytes. Indeed, when we analyzed these published datasets, we
observed increased H3K27 acetylation in the promoters of
normal monocytes compared to normal MG for the core BMDM
genes (Figure S2E). Similarly, there was increased H3K27 acety-
lation in the promoters of core MG genes in MG compared to
monocytes (Figure S2E). Enhancer specification and epigenetic
states inMGand othermacrophage populations have been asso-
ciated with differential PU.1 occupancy. Interrogating previously
published data (Gosselin et al., 2014), we observed that several
macrophage subsets (including BMDM) all showed increased
PU.1 binding at the promoters of our core BMDM genes
compared to normal MG (Figure S2F). Meanwhile, variability in
PU.1 occupancy wasminimal at the promoters of coreMGgenes
(Figure S2F). Similar binding dynamics were evident in enhancer
elements, where PU.1 occupancy in enhancer regions of core
BMDM genes was higher in BMDMs than MG, with less pro-
nounced differences present in core MG genes (Figure S2G).
Thus, epigenetic landscapes established before the development
of a tumor may play a role in regulating differential activation pat-
terns subsequently observed in malignancy.
Identification of Transcription Factor Networks
Underlying TAM Activation
Given the epigenetic differences in the non-malignant setting,
we next determined if chromatin states also differed between
TAM BMDMs and TAM MG. We performed assay for transpo-
sase-accessible chromatin sequencing (ATAC-seq) (Buenrostro
et al., 2013) to assess chromatin accessibility in TAM BMDMs
and TAM MG sorted from the GL261 model (Figure 1D). We
found the ATAC-seq signal was associated with cell-type-spe-
cific gene expression. In TAM BMDMs, the promoters of core
BMDM and TAM BMDM genes had higher ATAC-seq signal
than core MG and TAM MG genes, while TAM MG promoters
of core MG and TAM MG genes had a higher ATAC-seq signal
than core BMDMand TAMBMDMgenes (Figure S3A).Within en-
hancers and intronic elements of these gene sets, we identified
120 BMDM-specific peaks in TAM BMDM genes, including
Vav3, and 704 MG-specific peaks in TAM MG genes, including
P2ry12 and Sall1 (Figures 3A, S3B, and S3C; Table S5A).
We analyzed the transcription factor (TF) landscape underlying
these different peaks and performed de novomotif analysis (mo-
tifs are shown in all capital letters). Motif analysis of these peaks
revealed an enrichment of FOS/JUN and PU.1 binding sites in
both TAMBMDMand TAMMGpeaks (Figure 3B; Table S5B), re-
inforcing previous analyses demonstrating the critical role of
PU.1 in establishing specific enhancer landscapes in tissue-resi-
dent macrophages (Gosselin et al., 2014). Besides these shared
enrichments, we found TAM BMDM peaks enriched for RUNX
and CREB/bZIP motifs, while TAM MG peaks were enriched
for SMAD3 and MEF2A motifs (Figure 3B).
To determine if these motifs reflected pathway activation of
particular TFs we modeled the expression of their predicted
downstream targets (see Supplemental Experimental Proced-
ures). We identified TF families with enriched activity in TAM
Figure 3. Cell-Specific Transcription Factor Activities Underlie Differences between TAM BMDMs and TAM MG
(A) Heatmap depicting ATAC-seq signal 1 kb upstream and downstream of peaks specifically enriched in GL261 TAM BMDMs (left) and GL261 TAMMG (right).
Peaks were selected based on association with differentially expressed genes between TAM BMDMs (top, green) and TAM MG (bottom, red).
(B) Motifs identified by HOMER to be enriched in TAM BMDM and TAM MG peaks shown in (A).
(C) Boxplots depicting normalized TF activity scores for indicated motifs across TAM BMDMs and TAM MG from GL261 and GEMM-shP53 gliomas.
(D) Heatmap depicting row-normalized log2 gene expression values for indicated genes in four different TAM populations.
(E and F) ATAC-sequencing tracks from TAM BMDMs (top, green) and TAM MG (bottom, red) from GL261 gliomas for (E) Runx3 and (F) Hdac11. Shaded gray
regions indicate peaks specifically referenced in text. The y axis values indicate tags per 10,000,000 with a range of 0–50. TSS denotes transcription start site.
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BMDMs relative to TAM MG in the GEMM-shP53 and GL261
models (and vice versa) (Figures 3C and S3D). Among a panel
of different TFs, EGR1 and MEF2A were enriched in TAM MG
(Figures 3C and S3D; Table S5C). Interestingly, MEF2 is associ-
ated with MG identity (Lavin et al., 2014). In TAM BMDMs, TF
motifs involved in monocyte to macrophage differentiation
were enriched, including RUNX, CEBP, and PU.1 (Figures 3C
and S3D) (Alder et al., 2008). STAT3 and IRF4 were also enriched
(Figure 3C), both of which have been associated with differential
functions in macrophage activation (Mosser and Edwards, 2008;
Ostuni andNatoli, 2011).We complemented these genome-wide
TF activity analyses with motif enrichment analysis on the pro-
moters of TAM BMDM-specific and TAM MG-specific genes
using HOMER (Heinz et al., 2010) (Figure S3E). This also revealed
an enrichment of MEF2 motifs in TAM MG, demonstrating the
consistent role of tissue-specific transcriptional programs in
TAM MG education. Meanwhile, TAM BMDM-specific genes
were again enriched in PU.1, RUNX, and CEBP motifs (Fig-
ure S3E). These findings were further corroborated by increased
expression of brain-specific TFs (Mef2c, Sall1, and Sall3) in TAM
MG, while TAM BMDMs were enriched for Ciita, Vdr, Ahr, and
Runx family members (Figure 3D; Table S2A).
Given the consistent enrichment of RUNX activity in TAM
BMDMs,wenext focusedonexamining the expression andchro-
matin state of Runx family members. Runx2 and Runx3 were en-
riched in TAM BMDMs compared to TAM MG (Figure 3D). While
no differences were found in the chromatin state of Runx1 or
Runx2, in the first intron of Runx3 (Figure 3E, ii), we observed a
peakpresent in TAMMGbut reduced in TAMBMDMs (Figure 3E).
Meanwhile, the Runx3 promoter showed little open chromatin in
TAM MG and a distinct peak in TAM BMDMs near the transcrip-
tion start site (Figure 3E, i). Interestingly, both peaks have been
shown to be transforming growth factor b (TGF-b)-responsive
PU.1 binding sites associated with Runx3 expression (Chopin
et al., 2013), indicating the same signal transduction pathway
can produce distinct outputs in TAM BMDMs and TAM MG.
We also identified enrichment of the epigenetic modifiers
Hdac7 and Hdac9 in TAM BMDMs, while Hdac11 was enriched
in TAM MG (Figure S3F), the latter of which has been shown to
repress Il10 expression in macrophages (Villagra et al., 2009).
Interestingly, an upstream enhancer element in Hdac11 was
significantly enriched in TAM MG compared to TAM BMDMs, a
peak that contained a SMAD-responsive element (Figure 3F-i).
Collectively, these results suggest that differential genomic
PU.1 occupancy underlies distinct open chromatin states in
BMDMs and MG, whereupon additional factors such as TGF-
b/SMAD signaling and RUNX family members cooperate with
PU.1 to enforce distinct transcriptional networks. Subsequent
regulation of TFs and chromatin modifying factors, such as
Hdac11, may explain the distinct cytokine expression patterns
observed, such as TAM BMDM expression of Il10 and TAM
MG expression of Tnf.
Itga4/Cd49d Distinguishes Microglia and Peripherally
Derived Macrophages in Murine Models of Brain
Malignancy
We next sought to identify tools capable of distinguishing TAM
BMDMs and TAM MG in human disease, where genetic lineage2452 Cell Reports 17, 2445–2459, November 22, 2016tracing is not possible. Given that TAM BMDMs in gliomas upre-
gulated Cx3cr1 (Figure S1F), a proposed MGmarker, we sought
to identify TAM BMDM-specific markers that instead remained
silent in TAMMG. From the 164 core BMDMgenes, we identified
40 candidate transmembrane proteins that might serve as useful
markers for flow cytometry. Among these, the integrin subunit
alpha 4, Itga4/Cd49d, emerged as a promising candidate, partic-
ularly given previous reports that it, along with the integrin sub-
unit alpha L, Itgal/Cd11a, is regulated by RUNX family members,
including Runx1 and Runx3 (Domı´nguez-Soto et al., 2005).
Consistently, we found that Itga4 and Itgal were specifically
repressed in MG compared to other macrophage populations
(Figure S4A). This was confirmed by flow cytometry, where
Cd49d expression in MG was negligible or absent compared
to macrophages of the spleen, liver, lung, bone marrow, and
blood Ly6C+ monocytes (Figure 4A). Ly6G+ granulocytes were
also Cd49d, which, along with Cd49d+ lymphocytes in the
Cd45+Cd11b gate, served as useful gating controls in subse-
quent experiments (Figure 4A).
We examined Cd49d and Cd11a expression in TAM BMDMs
and TAM MG using Flt3:Cre-based lineage tracing in the
GEMM-shP53 model. After gating on Cd45+Cd11b+Ly6C
Ly6G cells, the normal brain only contained Cd45lowCd49d
cells, and all peripheral monocytes were Cd45highCd49d+
(Figure 4B). In tumors, we found two cell populations,
Cd45lowCd49d and Cd45highCd49d+, which contained GFP
TdTomato+ MG and GFP+ TdTomato BMDMs, respectively
(Figure 4B). Similar results were found for Cd11a (Figure 4B)
and were replicated in the GL261 model using both Cx3cr1-
based and Flt3:Cre lineage-tracing strategies (Figures S4B
and S4C). Lastly, we evaluated Cd49d expression in a Pten
loss-of-function PDGFB-driven glioma model (GEMM-PtenFlox)
where PtenFlox/Flox; nTva+ mice were injected with RCAS
vectors encoding PDGFB and Cre (Huse et al., 2009). Using
IR-BMT for lineage tracing, we found that Cd49d distinguishes
donor and host-derived cells, including in glioma models with
extended latency (12 weeks for the GEMM-PtenFlox model)
(Figure S4D).
To evaluate other models of brain malignancy, we utilized an
intracardiac injection model of brain metastasis (BrM) coloniza-
tion using a tumor cell line (99LN-BrM). 99LN-BrM cells were
originally derived from the lymph node of a MMTV:PyMT breast
cancer GEMM and subjected to in vivo selection. We used this
syngeneic, immunocompetent BrM model in conjunction with
Cx3cr1-based lineage tracing and found that BrM lesions con-
tained both TdTomato+ Iba1+ and TdTomato Iba1+ cells, indi-
cating recruitment of both TAM MG and TAM BMDMs, respec-
tively (Figures 4C and 4D). We validated these findings by flow
cytometry, where Cd49d and Cd11a served as reliable markers
of BMDMs as in the glioma models described above (Figure 4E).
We again found that eYFP levels, a direct readout of Cx3cr1
expression, were similar between TAM BMDMs and TAM MG
in BrM, reinforcing the necessity of the Cx3cr1:CreER lineage
tracing approach over that of the Cx3cr1 reporter (Figure S4E).
Lastly, we confirmed these data in a well-established xenograft
BrM model using brain homing MDA-MB-231 cells (Bos et al.,
2009), in conjunction with IR-BMT lineage tracing using mRFP+
donor cells. In this model, we identified two cell populations,
Figure 4. Itga4/Cd49d Distinguishes TAM BMDMs and TAM MG in Murine Brain Malignancy
(A) Histogram of Cd49d expression for indicated populations from non-tumor-bearing mice.
(B) Flow cytometry for Cd45 and either Cd49d (top) or Cd11a (bottom) in normal bloodmonocytes, normalMG (from adjacent normal brain), or TAMs isolated from
Flt3:Cre Rosa26:mTmG mice with GEMM-shP53 tumors. Adjacent histograms indicate GFP expression in indicated populations.
(C) Experimental schematic for the 99LN-BrM model in Cx3cr1-lineage tracing mice.
(D) Representative IF staining of TdTomato (red), Iba1 (white), and DAPI (blue) 99LN-BrM tumors as depicted in (C). Scale bar, 50 mm.
(E) Flow cytometry as in (B) for the 99LN-BrMmodel, with TdTomato expression indicated in the adjacent histogram. Flow plots are representative of n = 5–8mice.Cd45lowCd49d MG and Cd45highCd49d+ BMDM. The mRFP+
donor cells were exclusively found within the Cd45highCd49d+
BMDM gate (Figure S4F).
Together, our results obtained in multiple models of brain ma-
lignancy with distinct lineage-tracing approaches demonstrate
that TAM BMDM accumulation is independent of BBB precon-
ditioning by IR or intracranial injection. These data also thor-
oughly establish Cd49d as an efficient marker to distinguish resi-
dent MG and peripherally derived macrophages in homeostasis
as well as in primary and metastatic brain malignancies.CD49D Identifies Microglia and Macrophages in Human
Brain Malignancies
We next investigated whether CD49D could be used to discrim-
inate MG and peripherally derived macrophages in human brain
tumors. We assessed CD49D expression by flow cytometry
across a panel of surgical samples composed of non-malignant
normal brain (n = 3), untreated high-grade glioma (GBM) (n = 3),
lung adenocarcinomas (n = 6), and peripheral blood mononu-
clear cells (PBMCs) (n = 6). Consistent with our data in mice,
granulocytes (CD45+CD11B+CD66B+CD14lowCD16+) did notCell Reports 17, 2445–2459, November 22, 2016 2453
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express CD49D, and were used as a reference guide for gating
CD49D+ and CD49D TAMs (Figure S5A). Importantly, we never
identified CD49D TAMs in primary lung tumors or CD49D
monocytes in healthy donor PBMCs, indicating that, as pre-
dicted, low expression of CD49D is restricted to MG and is not
a general phenotype of tissue-residentmacrophages (Figure 5A).
By contrast, the CD45+CD11B+CD66BCD14+CD16 compart-
ment in non-malignant brain was predominantly composed of
CD49D MG (Figure 5A). Critically, in each GBM sample we
identified both CD49D+ and CD49D TAMs, presumably repre-
senting BMDM and brain-resident MG, respectively (Figure 5A).
Interestingly, inhumansamples,we foundnodifference inCD45
expression between CD49D and CD49D+ TAMs (Figure 5B), a
marker previously suggested to be informative for distinguishing
BMDMs andMG in brainmalignancy (Hussain et al., 2006; Parney
et al., 2009; Sedgwick et al., 1991). Indeed, CD45 expression
differed most prominently between granulocytes and TAMs, as
opposed toMGandBMDMs (Figure 5B). However, this lack of dif-
ferential CD45 expression is not the case in mouse, where Cd45
adequately discriminates MG and BMDM in the models tested
(Figure 5B). We next sorted paired CD49D and CD49D+ TAMs
from GBM patients to verify these populations indeed reflected
TAM MG and TAM BMDMs, respectively. Using genes specific
forTAMMGandTAMBMDMs fromourmousemodels (Figure2A),
we found that CD49D TAMs were indeed enriched for TAM MG
genes (p% 7.783 103), while CD49D+ TAMs were enriched for
TAM BMDM genes (p% 5.013 103) (Figure 5C).
Previous analyses of TAM expression in human gliomas have
utilized bulk CD11B+ cells, a population likely composed of both
TAM BMDMs and TAM MG, as well as other myeloid popula-
tions. We queried one available RNA-seq dataset from bulk
CD11B+ cells (Szulzewsky et al., 2016), which showed increased
ITGA4/CD49D expression in purified CD11B+ cells in GBM
compared to normal MG from either post-mortem samples or re-
sections from epileptic patients (Figure S5B). This was comple-
mented by a relative decrease in the MG-enriched transcript
P2RY12 in GBM compared to non-malignant brain (Figure S5B).
In querying an additional microarray-based dataset of purified
CD11B+ cells (Gabrusiewicz et al., 2016), we observed that
peripheral blood CD11B+ cells from GBM patients expressed
similar levels of ITGA4 compared to GBM tumor samples, while
therewas higherP2RY12 expression inGBMsamples than in pe-Figure 5. CD49D Discriminates TAM BMDMs and TAM MG in Human B
(A) Classical monocytes, MG, and TAMs were defined as CD45+CD11B+CD66B
sentative samples of human classical monocytes from peripheral blood (n = 6), TA
(n = 3), and TAMs from a GBM patient (n = 3).
(B) Histogram of CD45 expression by flow cytometry in human (left) and
granulocytes (CD45+CD11B+CD66B+CD16+CD14low), lymphocytes (CD45+CD
BMDMs (CD45+CD11B+ CD66BCD16CD14+CD49D+). In mouse, Cd45 expre
(Cd45+Cd11b), TAM MG (Cd45+Cd11b+Ly6CLy6GTomato+GFP), and
Rosa26:mTmG GEMM-shP53 glioma. Data are representative of n = 3 patients a
(C) Z scored single sample gene set enrichment analysis (ssGSEA) scores for TAM
paired t test, p% 7.78 3 103) in matched CD49D and CD49D+ TAMs from GB
(D) Scatterplot of TAM BMDM signature score (x axis, left, Spearman rho = 0.5
rho = 0.067, p% 0.411) and ITGA4 expression (y axis) from TCGA-GBM RNA-se
confidence intervals.
(E and F) Z scored TAM BMDM signature scores across (E) GBM subtype (AN
5.93 3 103).ripheral blood (Figure S5C), as we would have expected. We
extended these analyses to whole-tissue RNA-seq data from
the TCGA-GBM cohort (Brennan et al., 2013) and observed
that ITGA4 expression was significantly increased in GBM
compared to normal brain (Figure S5D). Collectively, these ana-
lyses suggest that TAMs in GBM represent a heterogeneous
population composed of both BMDMs and MG, reinforcing the
necessity of refined sorting strategies for accurate discrimination
between these cells and highlighting the utility of a CD49D-
based gating approach.
We next assessed TAM BMDM and TAMMG gene set expres-
sion in the TCGA cohort as a whole. TAMBMDM genes and TAM
MG genes showed high intra-gene set correlation, where TAM
BMDM genes such as RUNX2, IL10, RUNX3, ITGA4, and VDR
showed significant pairwise correlations and TAM MG genes
such asMEF2C, P2RY12,RXRG, SALL1,KLF12 andSALL3 simi-
larly showed significant pairwise correlations (Figure S5E). More-
over, ITGA4 showed a high correlation with a TAM BMDM gene
signature score (p% 2.23 1016), but not with a TAMMG signa-
ture score (Figure 5D), showing increased ITGA4 expression is
specific to TAM BMDM abundance and not TAMs as a whole.
Previous transcriptional and epigenetic analyses have identi-
fied distinct GBM subtypes (Noushmehr et al., 2010; Verhaak
et al., 2010), where the mesenchymal subtype was enriched
for tumor stroma and inflammatory molecules. Here, we find
TAM BMDM signature scores are significantly different among
molecular subtypes of GBM (p% 2.2 3 1016), with the highest
scores in the mesenchymal GBM subtype and the lowest scores
in G-CIMP patients (Figure 5E). Correspondingly, TAM BMDM
signature scores were lowest in patients with IDH1 mutations
(Figure 5F; p% 5.933 103). By comparison, TAMMG signature
scores displayed a blunted association with tumor subtype
(p % 0.041) and no association with IDH1 mutation status
(p % 0.153) (Figures S5F and S5G). These analyses reinforce
our findings that TAM BMDMs and TAM MG are distinguishable
immune cell populations with distinct abundance and character-
istics in specific subtypes of human GBM.
DISCUSSION
IR-BMT has been used widely in animal models to perform line-
age tracing of TAMs in brain malignancy (Ajami et al., 2007; Derain Malignancy
CD14+CD16. Gated cells are then shown for CD14 and CD49D in repre-
Ms from a lung adenocarcinoma patient (n = 6), MG from a non-malignant brain
mouse (right) samples. In human GBM, CD45 expression is shown for
11B), TAM MG (CD45+CD11B+CD66BCD16CD14+CD49D), and TAM
ssion is shown for granulocytes (Cd45+Cd11b+Ly6ClowLy6G+), lymphocytes
TAM BMDMs (Cd45+Cd11b+Ly6CLy6GTomatoGFP+) from a Flt3:Cre
nd n = 5 mice.
BMDM genes (left, paired t test, p% 5.013 103) and TAMMG genes (right,
M patients. Dashed lines indicate matched samples (n = 3 patients).
64, p % 2.2 3 1016) and TAM MG signature score (x axis, right, Spearman
q data. Solid blue line indicates line of best fit, with shaded areas depicting SD
OVA p % 2.2 3 1016) and (F) IDH1 mutation status (Student’s t test p %
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Palma et al., 2005; Huang et al., 2014; Mildner et al., 2007; M€uller
et al., 2015), albeit with concerns regarding potential artifacts
due to effects of IR on BBB disruption. Alternative chemical
BMT approaches have been suggested, though similar effects
on BBB permeability cannot be ignored (Alder et al., 2008; Kier-
dorf et al., 2013b). Here, we confirm that IR-BMT leads to
increased TAM BMDM content in the GL261 glioma model, a
finding that has been recently reported by juxtaposing IR-BMT
with and without head-shielding (M€uller et al., 2015). While IR-
BMT may confound lineage-tracing studies, it remains to be
seen if IR preconditioning before the onset of tumorigenesis
significantly alters TAM activity in tumor development or if the in-
flammatory environment of the tumor supersedes any ante-
cedent effects of the IR-BMT protocol.
Other than IR-BMT, the most widely employed approach to
discriminate MG and peripherally derived macrophages relies
upon Cd45 expression, with Cd45high cells considered BMDMs
and Cd45low cells considered MG (Gabrusiewicz et al., 2011;
Sedgwick et al., 1991). While this marker seems adequate in
the murine models we have employed here, cell-type-specific
CD45 expression appears to be different between mouse and
human. Our data indicate that CD45 does not accurately
discriminate MG and BMDMs in patient samples, emphasizing
the need for extensive flow cytometry panels to clearly distin-
guish these cells in both species. Additionally, our genetic line-
age tracing models also show that expression of Cx3cr1, which
is commonly used to trace normal MG, is subject to upregulation
in BMDMs upon tumor education (Figures 2A, S1F, and S4E) and
thus cannot be used to discriminate MG and BMDMs in brain
tumors.
Instead, we present Itga4 (Cd49d) as an effective, consistent
marker that works in both mice and humans to distinguish MG
and peripherally derived macrophages in multiple brain malig-
nancies. Cd49d may also prove a useful tool in determining the
precise origin and kinetics of peripherally derived macrophages
in brain tumors. Recent efforts to understand the heterogeneity
and origins of non-parenchymal myeloid cells in the brain
(including perivascular, meningeal, and choroid plexus macro-
phages) revealed that a subset of these cells are labeled using
similar Flt3-Cre and Cx3cr1-CreER based lineage tracing sys-
tems as employed here (Goldmann et al., 2016). Thus it will be
of interest to determine if any of these populations, in addition
to monocytes, contribute to the TAM pool.
Our data support the hypothesis that epigenetic states influ-
ence stimulus-dependent transcriptional induction, thus leading
to differential TAM education between MG and BMDMs. Differ-
ential genomic occupancy of PU.1 between MG and other
macrophage populations in non-cancer contexts has been
shown to dictate differential enhancer selection (Gosselin
et al., 2014). Indeed, within this dataset, we found that PU.1 bind-
ing sites at enhancers and promoters were already different be-
tween MG and BMDM for the genes we identified to be specific
to their respective TAM populations. This suggests that TAM
BMDMs and TAM MG are poised to engage in different tran-
scriptional networks based on initial enhancer selection. It is
likely that differential expression of binding partners influences
PU.1 genomic occupation. Cooperative binding is evident be-
tween PU.1 and CEBPb to promote macrophage differentiation2456 Cell Reports 17, 2445–2459, November 22, 2016and in B cell development, where PU.1 occupancy is influenced
by E2A expression (Heinz et al., 2010). Such a hypothesis has
also been shown to account for MG-specific PU.1 binding
in cooperation with TGF-b-induced SMAD activity (Gosselin
et al., 2014). Similar dynamics may be at play in brain tumors,
where binding partners that are absent in MG and expressed
in BMDMs can sculpt genomic PU.1 occupancy. For example,
the RUNX family member Runx3 is one such candidate, which
is enriched in TAM BMDMs versus TAM MG and shows
motif enrichment in promoters where PU.1 binds in BMDMs,
but not MG.
While our studies here focus predominantly on identifying
recurrent signatures distinguishing TAM MG and TAM BMDMs
across multiple mouse models and patient samples, there
were also tumor-specific gene expression patterns in TAM edu-
cation (Figures 2E, S2C, and S2D), which may provide insights
into how tumor-derived signals can generate inter-tumoral
heterogeneity in TAM activation profiles. In addition, analysis of
TCGA data showed that gene signatures associated with TAM
BMDMs were differentially enriched in the distinct tumor sub-
types of GBM. Recent reports have identified mixed activation
states in bulk TAM populations in glioma patients (Gabrusiewicz
et al., 2016; Szulzewsky et al., 2016), and our data now show that
TAM MG and TAM BMDMs possess distinct activation states,
potentially resolving this mixed phenotype. Importantly, the
identification of CD49D as a cell-surface marker to discriminate
between TAM MG and TAM BMDMs in human disease will
permit extensive interrogation of these cell populations in patient
samples.
Collectively, the studies presented here definitively demon-
strate that peripherally derived macrophages are indeed present
in multiple mouse and human brain malignancies and have
distinct transcriptional profiles from their brain-resident counter-
parts. We posit that while macrophages can acquire tissue-
resident macrophage-like traits upon entry into a tissue (Lavin
et al., 2014), an inflammatory microenvironment, such as in the
context of cancer or neuroinflammation, may further amplify dif-
ferences between the cells, leading to diverse functional out-
comes for tissue-resident and peripherally derived macrophage
populations.
EXPERIMENTAL PROCEDURES
Tumor and Lineage Tracing Models
Mousemodels of gliomagenesis and brainmetastasis, cell line generation, and
the use of lineage tracing models have been previously reported (Boyer et al.,
2011; Parkhurst et al., 2013; Quail et al., 2016; Sevenich et al., 2014) and are
described in full in Supplemental Experimental Procedures.
Institutional Review Board Approval and Patient Information
All human specimens were collected from patients consented to Memorial
Sloan Kettering Cancer Center (MSKCC) institutional review board (IRB)
protocols #06-107, #14-230. Glioma patients that presented with contrast-
enhancing brain lesions and no prior history of brain malignancy or therapy
were included. Tumor specimens were collected from the operating room
and processed as described below. Pathological analyses confirmed grade
IV GBM. Non-malignant normal brain samples were collected from two sour-
ces: non-malignant sites distant from low-grade disease and post-mortem
samples with no history of brain malignancy. Pathological analysis confirmed
the absence of tumor. Samples from patients with primary lung tumors were
included based on pathological analysis of lung adenocarcinoma, with no
screening based on prior malignancy or therapy.
Flow Cytometry and Cell Sorting
For blood analysis, mice were bled via either retro-orbital or submandibular
routes under isoflurane anesthesia. For all other tissue analyses, mice were
anesthetized with 1.25% avertin and transcardially perfused with PBS. Sin-
gle-cell suspensions from spleen and bone marrow were isolated by macro-
dissection and mechanical tissue dissociation. Liver, kidney, and lung were
macrodissected and dissociated using the Mouse Tumor Dissociation Kit
(mTDK; Miltenyi) and the OctoMACS dissociator. Mouse and human brain
specimens were macrodissected and dissociated using the Brain Tumor
Dissociation Kit (BTDK; Miltenyi) and a single-cell suspension generated using
the OctoMACS dissociator. Human lung tumors were dissociated with the
Human Tumor Dissociation Kit (hTDK; Miltenyi.) All tissue suspensions were
filtered through a 40-mMmesh filter and underwent red blood cell lysis (Pharm-
Lyse BD). Normal brain and brain tumor tissues were incubated with Myelin
Removal Beads (Miltenyi). Single-cell suspensions were FC blocked (BD
#553141) for 15 min at 4C and then incubated with directly conjugated anti-
body panels for 15 min at 4C. Cell suspensions were washed (PBS + 2% fetal
bovine serum) and resuspended in a DAPI solution. All flow cytometry analysis
was completed on a BD Fortessa device, and all sorting was performed on an
Aria III. Cells were sorted directly into TRIzol LS and snap frozen in liquid
nitrogen. Antibodies and methods for immunohistochemistry can be found
in Supplemental Experimental Procedures.
Statistical Methods
RNA Sequencing, ATAC Sequencing, and Bioinformatics
RNA was isolated by chloroform extraction and isopropanol precipitation.
RNA-sequencing libraries were generated with the SMART-Seq preparation
kit (CloneTech). Single-end, 100-bp sequencing was performed by GeneWiz
on an Illumina HiSeq 2500. FASTQ files were mapped to the mouse genome
(mm10) or the human genome (hg19) using STAR (version 2.5.0e) with default
parameters (Dobin et al., 2013). Transcript abundance was quantified using
STAR with a GTF file from iGenomes (Illumina). A count matrix was produced
in R and differential gene expression was assessed with DESeq2 using a fold
change cutoff of ±2 and a false discovery rate of 5% (Love et al., 2014). Gene
Ontology analysis was performed using DAVID with default parameters (Den-
nis et al., 2003). ATAC-sequencing was performed as previously described
(Buenrostro et al., 2013). Paired-end, 50-bp sequencing was performed on
an Illumina HiSeq 2500 with an average read depth of 35,000,000 reads
per sample. Reads were mapped to mm10 using STAR (version 2.5.0e) using
(–alignIntronMax 1–alignEndsType EndToEnd). Peak calling, annotation, and
differential peak identification was performed using HOMER.
Methods for analyzing external datasets, TF activity analysis, and additional
statistical methods are described in Supplemental Experimental Procedures.
ACCESSION NUMBERS
The accession number for the gene expression and ATAC-sequencing data
generated in this study is GEO: GSE86573.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
five figures, and five tables and can be found with this article online at http://
dx.doi.org/10.1016/j.celrep.2016.10.052.
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